Event JSON
{
"id": "0802a3ac1e579827133575d610b9012c1e327b3efc3bb67b5221dbd1ab787d5f",
"pubkey": "61e9f37dc1239bee14634b27a3ea2a5f7d06e254648349b3886c042939936499",
"created_at": 1764867684,
"kind": 1,
"tags": [
[
"proxy",
"https://wandering.shop/@adapalmer/115662368549777930",
"web"
],
[
"t",
"sharegoodnewstoo"
],
[
"proxy",
"https://wandering.shop/users/adapalmer/statuses/115662368549777930",
"activitypub"
],
[
"L",
"pink.momostr"
],
[
"l",
"pink.momostr.activitypub:https://wandering.shop/users/adapalmer/statuses/115662368549777930",
"pink.momostr"
],
[
"-"
]
],
"content": "Powerful new malaria drug offers first serious alternative to artemisinin in decades. Novartis’ new drug cured more than 97% of malaria cases in a Phase 3 trial of 1,688 adults and children across 12 African countries, matching or beating current artemisinin-based therapies while killing drug-resistant strains and blocking transmission stages. If regulators approve, it will be the first frontline malaria drug of its kind in over 25 years. Reuters https://www.reuters.com/business/healthcare-pharmaceuticals/new-effective-anti-malaria-drug-could-help-fight-rising-resistance-says-novartis-2025-11-12/\n#ShareGoodNewsToo",
"sig": "bafab5a916f1a255948ee8d9455f0c73d7d270bf6660a115c14073148c7d59628af067767f1b21b0f36fbbb7fbcd419c3910a5d56f916c4a2cd2508e6c3b6293"
}